Fennec Pharmaceuticals (FENC) Tops Q1 EPS by 48c

Fennec Pharmaceuticals (NASDAQ: FENC) reported Q1 EPS of $0.41, $0.48 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $25.4 million versus the consensus estimate of $10.09 million.

For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.

You May Also Be Interested In

• ManpowerGroup (MAN) Tops Q2 EPS by 4c; offers guidance
• Medtronic acquires SPR Therapeutics for $650 million
• GE Aerospace beats estimates, lifts guidance on services growth